Actinium Pharmaceuticals Stock Alpha and Beta Analysis
| ATNM Stock | USD 1.41 0.03 2.08% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Actinium Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Actinium Pharmaceuticals over a specified time horizon. Remember, high Actinium Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Actinium Pharmaceuticals' market risk premium analysis include:
Beta 0.98 | Alpha (0.48) | Risk 4.25 | Sharpe Ratio (0.07) | Expected Return (0.31) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Actinium |
Actinium Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Actinium Pharmaceuticals market risk premium is the additional return an investor will receive from holding Actinium Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Actinium Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Actinium Pharmaceuticals' performance over market.| α | -0.48 | β | 0.98 |
Actinium Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Actinium Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Actinium Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Actinium Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Actinium Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Actinium Pharmaceuticals shares will generate the highest return on investment. By understating and applying Actinium Pharmaceuticals stock market price indicators, traders can identify Actinium Pharmaceuticals position entry and exit signals to maximize returns.
Actinium Pharmaceuticals Return and Market Media
The median price of Actinium Pharmaceuticals for the period between Thu, Sep 5, 2024 and Wed, Dec 4, 2024 is 1.79 with a coefficient of variation of 9.2. The daily time series for the period is distributed with a sample standard deviation of 0.16, arithmetic mean of 1.74, and mean deviation of 0.13. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Actinium Pharmaceuticals Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Help With An Investigation | 09/10/2024 |
2 | Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Impacted Stockholders Are Urged To Contact The Schall Law Firm | 09/27/2024 |
3 | The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Incs Possible Securities Fraud | 10/14/2024 |
4 | The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud | 10/18/2024 |
5 | The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud | 10/22/2024 |
6 | Actinium Pharmaceuticals, Inc. Is Being Investigated For Violations Of Securities Laws And Affected Shareholders Should Contact The Schall Law Firm | 10/30/2024 |
7 | Insider Trading | 11/01/2024 |
8 | Telix and Eckert Ziegler to Partner on Actinium-225 Production Technology | 11/13/2024 |
9 | Actinium Pharmaceuticals Inc Quarterly 10-Q Report - Quartz | 11/14/2024 |
10 | Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 | 11/18/2024 |
11 | NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 | 11/21/2024 |
About Actinium Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Actinium or other stocks. Alpha measures the amount that position in Actinium Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 (projected) | Dividend Yield | 3.9E-5 | 1.2E-5 | Price To Sales Ratio | 108.06 | 1.7K |
Actinium Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Actinium Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Actinium Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Actinium Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Actinium Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Actinium Pharmaceuticals' management manipulating its earnings.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Actinium Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Actinium Pharmaceuticals Backtesting, Actinium Pharmaceuticals Valuation, Actinium Pharmaceuticals Correlation, Actinium Pharmaceuticals Hype Analysis, Actinium Pharmaceuticals Volatility, Actinium Pharmaceuticals History and analyze Actinium Pharmaceuticals Performance. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Actinium Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.